EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Impact of a dietary intervention with French maritime pine bark extract (Pycnogenol®) on bone turnover markers in women with osteoporotic bone loss: a randomized, placebo-controlled double-blind study—Part I

Christian Scherg, Franca Genest, Jonas Maghary, Lothar Seefried, Denitsa Docheva, Markus Krischke, Petra Högger

Frontiers in Nutrition · 12.10.2026 · 13

DOI: 10.3389/fnut.2026.1923949 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Frontiers in Nutrition, online erschienen am 12.10.2026. Verfasst von Christian Scherg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacy and Food Chemistry, University of Würzburg, Würzburg, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Osteoporosis is a highly prevalent health concern both in terms of disability to an individual and costs to society. While antiresorptive drugs are the standard treatment, nutritional supplementation may offer additional advantages, particularly in the pre-therapeutic stage of osteopenia or clinically stable osteoporosis. The French maritime pine bark extract Pycnogenol ® exhibits antioxidant and anti-inflammatory properties, but its influence on bone turnover has not been investigated in humans yet.

Methods

In this randomized, placebo-controlled, double-blind clinical trial, 67 women received either Pycnogenol ® (100 mg twice daily; n = 33) or placebo ( n = 34) during a 3-month placebo-controlled phase, followed by a 3-month active-treatment extension, in which all participants took Pycnogenol ® . The primary endpoint included changes in the bone resorption marker C-terminal telopeptide of type I collagen (CTX-1) and bone formation marker procollagen type I N propeptide (P1NP) in serum. Secondary endpoints comprised other bone turnover markers (N-terminal telopeptide of type I collagen, NTX-1; tartrate-resistant acid phosphatase 5b, TRAP5b; bone sialoprotein, BSP), an inflammatory marker (interleukin-6, IL-6), the microbial metabolite 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone (M1), and in vitro differentiation experiments with human mesenchymal stromal cells (hMSCs).

Results

Within the Pycnogenol ® group, serum CTX-1 levels were significantly reduced after both three ( p = 0.0327) and 6 months ( p = 0.0227) compared to baseline, while no between-group differences were observed at any visit. No significant changes were observed in P1NP concentrations. Additionally, a significant reduction from baseline was observed for NTX-1 serum levels in the Pycnogenol ® group at the end of the active-treatment extension ( p = 0.0100). Salivary M1 concentrations were significantly higher following 3 months of Pycnogenol ® supplementation compared to placebo ( p = 0.0289) and showed an inverse association with CTX-1 concentrations ( r = −0.216, p = 0.013, n = 131).

Conclusion

Dietary supplementation with Pycnogenol ® was associated with reductions in key bone resorption markers within the treatment group, while metabolite concentrations in saliva increased. Furthermore, Pycnogenol ® components enhanced the osteogenic differentiation of hMSCs in vitro . These findings suggest a potential protective effect of Pycnogenol ® on bone turnover in osteopenia and clinically stable osteoporosis. Clinical trial registration https://drks.de/search/de/trial/DRKS00026630 , DRKS00026630.

Schlagwörter

Stichwörter der Autor:innen

Pycnogenol®bone resorption markersbone turnoverdietary supplementationhuman mesenchymal stromal cellsosteogenic differentiationosteoporosis

Autor:innen und Institutionen

  • Institute of Pharmacy and Food Chemistry, University of Würzburg, Würzburg, Germany.
  • Osteology/Clinical Trial Unit, University of Würzburg, Würzburg, Germany.
  • Department of Musculoskeletal Tissue Regeneration, Orthopaedic Hospital König-Ludwig-Haus, University of Würzburg, Würzburg, Germany.
  • Julius-von-Sachs-Institute of Biosciences, Biocenter, Pharmaceutical Biology, University of Würzburg, Würzburg, Germany.

Zitieren

APA

Scherg, C., Genest, F., Maghary, J., Seefried, L., Docheva, D., Krischke, M., & Högger, P. (2026). Impact of a dietary intervention with French maritime pine bark extract (Pycnogenol®) on bone turnover markers in women with osteoporotic bone loss: a randomized, placebo-controlled double-blind study—Part I. Frontiers in Nutrition, 13. https://doi.org/10.3389/fnut.2026.1923949

Vancouver

Scherg C, Genest F, Maghary J, Seefried L, Docheva D, Krischke M, et al. Impact of a dietary intervention with French maritime pine bark extract (Pycnogenol®) on bone turnover markers in women with osteoporotic bone loss: a randomized, placebo-controlled double-blind study—Part I. Frontiers in Nutrition. 2026;13. doi:10.3389/fnut.2026.1923949

BibTeX
@article{Scherg2026,
  author = {Scherg, Christian and Genest, Franca and Maghary, Jonas and Seefried, Lothar and Docheva, Denitsa and Krischke, Markus and Högger, Petra},
  title = {Impact of a dietary intervention with French maritime pine bark extract (Pycnogenol®) on bone turnover markers in women with osteoporotic bone loss: a randomized, placebo-controlled double-blind study—Part I},
  journal = {Frontiers in Nutrition},
  year = {2026},
  volume = {13},
  doi = {10.3389/fnut.2026.1923949}
}
Kostenlos starten →